Edward Nassif, MD
Allergy & Immunology · Ames, IANPI 1295726255
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Optinose US, Inc. at 54.6% of the total. Reporting peaked in 2019 at $3,164 and has fallen 84.2% since, to $500 in 2025.
Across 108 payments — averaging $50.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$3K
- AstraZeneca$648
- Sanofi$442
- Pfizer$226
- GSK$212
- Amgen$201
- plus $731 from 19 others
What the payments were for
- Consulting fees$2,50046%
- Travel & lodging$3096%
- Food & beverage$2,49646%
- Education$1112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 7 | $2,956 |
| AstraZeneca | 13 | $648 |
| Sanofi | 31 | $442 |
| Pfizer | 10 | $226 |
| GSK | 7 | $212 |
| Amgen | 8 | $201 |
| Biocryst US Sales Co., LLC | 8 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $100 |
| Genentech USA, Inc. | 1 | $79 |
| Octapharma USA, Inc. | 2 | $58 |
| Boehringer Ingelheim | 1 | $43 |
| CSL Behring | 1 | $32 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| Alk-abello, Inc | 1 | $31 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| LEO Pharma Inc. | 1 | $27 |
| Chiesi USA, Inc. | 1 | $21 |
| Biocryst Pharmaceuticals, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Pharming Healthcare, Inc. | 1 | $15 |
| Grifols USA, LLC | 1 | $14 |
| Blueprint Medicines Corporation | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,416 in reported general payments places this provider in the 85th percentile of 32 allergy & immunology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 13 | $535,337 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 280 | $206,554 |
| Dupixent PenDupilumab | 18 | $101,569 |
| Breo ElliptaFluticasone/Vilanterol | 132 | $68,085 |
| Arnuity ElliptaFluticasone Furoate | 218 | $56,143 |
| NucalaMepolizumab | 11 | $41,387 |
| Advair HfaFluticasone Propion/Salmeterol | 62 | $33,653 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $20,150 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $19,362 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $12,849 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 90 | $10,375 |
| DuleraMometasone/Formoterol | 27 | $9,767 |
| Azelastine Hcl | 292 | $7,936 |
| Montelukast Sodium | 772 | $6,320 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 224 | $5,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $160 | $535,33713 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Nucala, Incruse Ellipta | $212 | $385,018678 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $648 | $39,51171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 32 allergy & immunology providers in Iowa.
Other allergy & immunology in Ames
- Jason CascioAmes$844
- Jay BrownAmes$623
- Vuong NayimaWest Des Moines$34K
- Fadi AlkhatibWest Des Moines$16K
- Daniel HamilosMason City$11K
- Lyla SchweigerCedar Rapids$6K
- Holly BrownCedar Rapids$4K
- Whitney MolisDes Moines$4K
- Safia NawazDes Moines$4K
- Andrea JonesDavenport$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.